Table 1 Patient demographics (safety analysis set).
Cohort A (N = 42) | Cohort A2 (N = 26) | Cohort B1 (N = 16) | Cohort C (N = 13) | |
|---|---|---|---|---|
Sex, n (%) | ||||
Male | 19 (45.2) | 15 (57.7) | 11 (68.8) | 7 (53.8) |
Female | 23 (54.8) | 11 (42.3) | 5 (31.3) | 6 (46.2) |
Ethnicity, n (%) | ||||
Black or African American | 1 (2.4) | 1 (3.8) | 0 (0.0) | 0 (0.0) |
Asian | 0 (0.0) | 0 (0.0) | 1 (6.3) | 0 (0.0) |
White | 37 (88.1) | 19 (73.1) | 9 (56.3) | 12 (92.3) |
Hispanic or Latino | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Other | 1 (2.4) | 0 (0.0) | 2 (12.5) | 1 (7.7) |
Not collected | 3 (7.1) | 6 (23.1) | 4 (25.0) | 0 (0.0) |
Age, median (years [min max]) | 58.5 (27, 75) | 63.0 (42, 81) | 61.0 (45, 78) | 61.0 (36, 70) |
At least one prior anticancer therapy, n (%) | ||||
≥1 | 41 (97.6) | 25 (96.2) | 16 (100.0) | NR |
≥3 | 19 (45.2) | NR | 8 (50.0) | NR |
≥6 | 2 (4.8%) | NR | 6 (37.5) | NR |
ECOG PS at baseline, n (%) | ||||
0 | 15 (35.7) | 10 (38.5) | 5 (31.3) | NR |
1 | 26 (61.9) | 16 (61.5) | 11 (68.8) | |
2 | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
3 | 1 (2.4) | 0 (0.0) | 0 (0.0) | |
